Skip to main content
Literatur
1.
Zurück zum Zitat Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55:453–61.CrossRef Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55:453–61.CrossRef
2.
Zurück zum Zitat Lai S-W. Proton pump inhibitors and the risk of pancreatic cancer. Journal of gastroenterology. 2021:In press. Lai S-W. Proton pump inhibitors and the risk of pancreatic cancer. Journal of gastroenterology. 2021:In press.
3.
Zurück zum Zitat Pottegård A, Broe A, Hallas J, et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9:671–8.CrossRef Pottegård A, Broe A, Hallas J, et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9:671–8.CrossRef
4.
Zurück zum Zitat Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.CrossRef Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.CrossRef
5.
Zurück zum Zitat Matuz M, Benkő R, Engi Z, et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102.CrossRef Matuz M, Benkő R, Engi Z, et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102.CrossRef
6.
Zurück zum Zitat Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76:449–57.CrossRef Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76:449–57.CrossRef
7.
Zurück zum Zitat Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:1756284818777943.CrossRef Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:1756284818777943.CrossRef
8.
Zurück zum Zitat Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Exp Rev Clin Pharmacol. 2018;11:1123–34.CrossRef Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Exp Rev Clin Pharmacol. 2018;11:1123–34.CrossRef
9.
Zurück zum Zitat Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: what if the results are true? Cancer Epidemiol. 2018;54:139–40.CrossRef Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: what if the results are true? Cancer Epidemiol. 2018;54:139–40.CrossRef
10.
Zurück zum Zitat Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Clinical research ed). 2019;365:l1580. Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Clinical research ed). 2019;365:l1580.
Metadaten
Titel
Proton pump inhibitors and the risk of pancreatic cancer
verfasst von
Nele Brusselaers
Omid Sadr-Azodi
Lars Engstrand
Publikationsdatum
02.02.2021
Verlag
Springer Singapore
Erschienen in
Journal of Gastroenterology / Ausgabe 3/2021
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-021-01761-8

Weitere Artikel der Ausgabe 3/2021

Journal of Gastroenterology 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.